update from barda, page-12

"We have some concerns about the project with regard to the product manufacturing, clinical study enrollment pace, costs, and contractor performance."

Should Biota take pride in the above statement?


"we are considering what is the best next step for the Biota project and the overall influenza antiviral drug development program before going forward with clinical studies in the Southern Hemisphere and manufacturing optimization and validation."

Sorta implies the Phase 2 trial might re-start? Which means Russell's statement the other night about finalising and releasing top line data might not happen just yet.